IL160271A0 - Pharmaceutical compositions containing pde4-inhibitors and nsaid - Google Patents

Pharmaceutical compositions containing pde4-inhibitors and nsaid

Info

Publication number: IL160271A0
Authority: IL; Israel
Prior art keywords: nsaid; inhibitors; pharmaceutical compositions; compositions containing; derivative
Prior art date: 2001-09-19

Application number

IL16027102A

Other languages

English (en)

Original Assignee

Altana Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-19

Filing date

2002-09-17

Publication date

2004-07-25

2002-09-17 Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag

2004-07-25 Publication of IL160271A0 publication Critical patent/IL160271A0/xx

Links

229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 3
239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 3
206010017865 Gastritis erosive Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000007107 Stomach Ulcer Diseases 0.000 abstract 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract 1
229960001259 diclofenac Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
201000005917 gastric ulcer Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 abstract 1
229960002586 roflumilast Drugs 0.000 abstract 1
231100000397 ulcer Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL16027102A 2001-09-19 2002-09-17 Pharmaceutical compositions containing pde4-inhibitors and nsaid IL160271A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01000473		2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en)	2001-09-19	2002-09-17	Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number	Publication Date
IL160271A0 true IL160271A0 (en)	2004-07-25

Family

ID=8176065

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16027102A IL160271A0 (en)	2001-09-19	2002-09-17	Pharmaceutical compositions containing pde4-inhibitors and nsaid
IL160271A IL160271A (en)	2001-09-19	2004-02-08	Pharmaceutical compositions containing pde4-inhibitors and

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL160271A IL160271A (en)	2001-09-19	2004-02-08	Pharmaceutical compositions containing pde4-inhibitors and

Country Status (24)

Country	Link
US (2)	US20040242597A1 (xx)
EP (1)	EP1429807B1 (xx)
JP (1)	JP4588998B2 (xx)
KR (1)	KR100949528B1 (xx)
CN (1)	CN100496607C (xx)
AT (1)	ATE355080T1 (xx)
AU (1)	AU2002337105B2 (xx)
BR (1)	BR0212606A (xx)
CA (1)	CA2459757C (xx)
CY (1)	CY1108011T1 (xx)
DE (1)	DE60218497T2 (xx)
DK (1)	DK1429807T3 (xx)
EA (1)	EA008108B1 (xx)
ES (1)	ES2282469T3 (xx)
HU (1)	HU229442B1 (xx)
IL (2)	IL160271A0 (xx)
MX (1)	MXPA04002562A (xx)
NO (1)	NO331756B1 (xx)
NZ (1)	NZ532278A (xx)
PL (1)	PL210463B1 (xx)
PT (1)	PT1429807E (xx)
SI (1)	SI1429807T1 (xx)
WO (1)	WO2003024489A2 (xx)
ZA (1)	ZA200402654B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004110424A1 (en) *	2003-05-28	2004-12-23	Glaxo Group Limited	Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
US20050059741A1 (en) *	2003-08-07	2005-03-17	B.M.R.A. Corporation B.V.	Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
CA2542277A1 (en) *	2003-10-21	2005-05-12	Pharmacia Corporation	Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
EP1683521A1 (en) *	2005-01-21	2006-07-26	Centre National De La Recherche Scientifique (Cnrs)	Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) *	2005-02-03	2006-08-09	Hikma Pharmaceuticals Co. Ltd.	Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
WO2006097459A1 (en) *	2005-03-14	2006-09-21	Nycomed Gmbh	Method for preventing cardiovascular diseases
JP2008543806A (ja) *	2005-06-17	2008-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	呼吸器疾患の治療のためのｍｒｐｉｖインヒビター
ATE502629T1 (de) *	2006-04-28	2011-04-15	Gruenenthal Gmbh	Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
FR2909876A1 (fr) *	2006-12-19	2008-06-20	Galderma Res & Dev S N C Snc	Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
EA018462B1 (ru)	2008-01-25	2013-08-30	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК МОДУЛЯТОРЫ СИНТЕЗА TNF-α И КАК ИНГИБИТОРЫ PDE4
WO2009109908A1 (en) *	2008-03-04	2009-09-11	Pfizer Limited	Methods of treating inflammatory pain
CA2753597A1 (en) *	2009-02-27	2010-09-02	Boehringer Ingelheim International Gmbh	Drug combinations containing pde4-inhibitors and nsaids
EP2400962B1 (de) *	2009-02-27	2017-11-08	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
BR112015019276A2 (pt)	2013-02-19	2017-07-18	Pfizer	compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2016012896A1 (en)	2014-07-24	2016-01-28	Pfizer Inc.	Pyrazolopyrimidine compounds
MD20170011A2 (ro)	2014-08-06	2017-08-31	Pfizer Inc.	Compuşi imidazopiridazinici
WO2019147824A1 (en)	2018-01-26	2019-08-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883635A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
EP4069213A1 (en) *	2019-12-03	2022-10-12	The USA, as represented by The Secretary, Department of Health and Human Services	Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
EP4188386A4 (en)	2020-07-28	2024-07-24	vTv Therapeutics LLC	CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF A QUINOLINE DERIVATIVE
US12102622B2 (en)	2021-02-10	2024-10-01	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) *	2021-09-22	2023-03-30	Iolyx Therapeutics, Inc.	Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1229075B (it) *	1985-04-05	1991-07-17	Fidia Farmaceutici	Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en)	1989-02-10	1990-09-05	Sterivet Lab Ltd	Cosmetic formulation
ES2137113B1 (es) *	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
IL135900A0 (en)	1997-11-04	2001-05-20	Pfizer Prod Inc	Indazole bioisostere replacement of catechol in therapeuticaly active compounds
JP2003503360A (ja)	1999-06-24	2003-01-28	ファルマシアコーポレイション	炎症性疾患の処置のための併用療法
CA2715683A1 (en) *	1999-08-21	2001-03-01	Nycomed Gmbh	Synergistic combination
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
AR029189A1 (es) *	1999-11-02	2003-06-18	Smithkline Beecham Corp	Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
US6410563B1 (en) *	1999-12-22	2002-06-25	Merck Frosst Canada & Co.	Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) *	1999-12-23	2002-04-16	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
CZ20022410A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
IL150963A0 (en) *	2000-02-08	2003-02-12	Smithkline Beecham Corp	Method and compositions for treating an inflammatory disease
ES2248231T3 (es) *	2001-01-31	2006-03-16	Pfizer Products Inc.	Derivados de eteres utiles como inhibidores de las isozimas pde4.
CZ20032491A3 (cs) *	2001-02-15	2004-01-14	Altana Pharma Ag	Ftalazinonpiperidinové deriváty

2002
- 2002-09-17 US US10/489,920 patent/US20040242597A1/en not_active Abandoned
- 2002-09-17 JP JP2003528583A patent/JP4588998B2/ja not_active Expired - Fee Related
- 2002-09-17 CA CA2459757A patent/CA2459757C/en not_active Expired - Fee Related
- 2002-09-17 WO PCT/EP2002/010424 patent/WO2003024489A2/en not_active Ceased
- 2002-09-17 KR KR1020047004047A patent/KR100949528B1/ko not_active Expired - Fee Related
- 2002-09-17 AU AU2002337105A patent/AU2002337105B2/en not_active Ceased
- 2002-09-17 EA EA200400410A patent/EA008108B1/ru not_active IP Right Cessation
- 2002-09-17 DE DE60218497T patent/DE60218497T2/de not_active Expired - Lifetime
- 2002-09-17 NZ NZ532278A patent/NZ532278A/en not_active IP Right Cessation
- 2002-09-17 AT AT02772313T patent/ATE355080T1/de active
- 2002-09-17 IL IL16027102A patent/IL160271A0/xx active IP Right Grant
- 2002-09-17 HU HU0401582A patent/HU229442B1/hu not_active IP Right Cessation
- 2002-09-17 DK DK02772313T patent/DK1429807T3/da active
- 2002-09-17 PL PL369472A patent/PL210463B1/pl unknown
- 2002-09-17 SI SI200230534T patent/SI1429807T1/sl unknown
- 2002-09-17 PT PT02772313T patent/PT1429807E/pt unknown
- 2002-09-17 CN CNB028182413A patent/CN100496607C/zh not_active Expired - Fee Related
- 2002-09-17 BR BR0212606-0A patent/BR0212606A/pt not_active IP Right Cessation
- 2002-09-17 MX MXPA04002562A patent/MXPA04002562A/es active IP Right Grant
- 2002-09-17 EP EP02772313A patent/EP1429807B1/en not_active Expired - Lifetime
- 2002-09-17 ES ES02772313T patent/ES2282469T3/es not_active Expired - Lifetime
2004
- 2004-02-08 IL IL160271A patent/IL160271A/en not_active IP Right Cessation
- 2004-04-05 ZA ZA2004/02654A patent/ZA200402654B/en unknown
- 2004-04-19 NO NO20041596A patent/NO331756B1/no not_active IP Right Cessation
2007
- 2007-05-07 CY CY20071100595T patent/CY1108011T1/el unknown
- 2007-12-20 US US12/003,129 patent/US8242146B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2282469T3 (es)	2007-10-16
KR20040053129A (ko)	2004-06-23
JP2005504077A (ja)	2005-02-10
WO2003024489A2 (en)	2003-03-27
HUP0401582A3 (en)	2008-04-28
KR100949528B1 (ko)	2010-03-25
CY1108011T1 (el)	2013-09-04
PL369472A1 (en)	2005-04-18
ZA200402654B (en)	2005-04-26
US20080255209A1 (en)	2008-10-16
AU2002337105B2 (en)	2008-03-20
PT1429807E (pt)	2007-05-31
PL210463B1 (pl)	2012-01-31
SI1429807T1 (sl)	2007-08-31
EP1429807A2 (en)	2004-06-23
CN100496607C (zh)	2009-06-10
DE60218497T2 (de)	2007-11-08
HU229442B1 (hu)	2013-12-30
ATE355080T1 (de)	2006-03-15
HUP0401582A2 (hu)	2004-11-29
IL160271A (en)	2008-03-20
EP1429807B1 (en)	2007-02-28
BR0212606A (pt)	2004-08-17
US8242146B2 (en)	2012-08-14
EA200400410A1 (ru)	2004-12-30
MXPA04002562A (es)	2004-05-31
WO2003024489A3 (en)	2003-09-18
CN1625411A (zh)	2005-06-08
DE60218497D1 (de)	2007-04-12
HK1066730A1 (en)	2005-04-01
JP4588998B2 (ja)	2010-12-01
CA2459757A1 (en)	2003-03-27
DK1429807T3 (da)	2007-06-18
US20040242597A1 (en)	2004-12-02
CA2459757C (en)	2011-08-30
EA008108B1 (ru)	2007-04-27
NZ532278A (en)	2006-02-24
NO331756B1 (no)	2012-03-19
NO20041596L (no)	2004-06-18

Legal Events

Date	Code	Title	Description
2008-11-03	FF	Patent granted
2008-12-29	KB	Patent renewed

Publication	Publication Date	Title
IL160271A0 (en)	2004-07-25	Pharmaceutical compositions containing pde4-inhibitors and nsaid
BRPI0411825A (pt)	2006-08-08	inibidores de p38 quinase a base de heterociclo de 5 elementos
CY1120241T1 (el)	2019-07-10	Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
CY1108274T1 (el)	2014-02-12	Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
MXPA04003668A (es)	2004-07-22	Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TW200511992A (en)	2005-04-01	Sulfonamide substituted imidazoquinolines
BR9914718A (pt)	2001-07-10	Formulações farmacêuticas de libertação controlada compreendendo um inibidor cgmp pde-5
DK1198233T3 (da)	2006-12-04	Sulfonamid- og sulfamidsubstituerede imidazoquinoliner
EE200100670A (et)	2003-02-17	Amiidasendatud imidasokinoliinid
IS7202A (is)	2004-03-31	Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
WO2003065987A3 (en)	2004-02-19	Granzyme b inhibitors
MXPA02009551A (es)	2004-05-14	Profarmacos de derivados de imidazopiridina.
NO20060392L (no)	2006-02-03	Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
SE0102808D0 (sv)	2001-08-22	New compounds
MXPA04003910A (es)	2004-07-23	Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
AR045724A1 (es)	2005-11-09	Composicion farmaceutica orodispersable de un compuesto antitrombotico
YU83903A (sh)	2006-08-17	Farmaceutske kombinacije zasnovane na derivatima piridoindolona
EA200100876A2 (ru)	2002-04-25	Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
EA200602082A1 (ru)	2007-04-27	Производные индол-2-она для лечения расстройств центральной нервной системы, желудочно-кишечных расстройств и сердечно-сосудистых расстройств